Lupron Depot

Phase 3Small molecule

RRepros Therapeutics Inc.

Lupron Depot is one of 103 small molecule programs targeting Uterine Fibroid. It is currently in Phase 3.

Indications

Total Trials

Active Trials

102

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine FibroidActive, not recruiting

Metastatic Prostate CancerActive, not recruiting

Prostate CancerActive, not recruiting

Uterine FibroidPhase 2

Active, not recruiting

Metastatic Prostate CancerPhase 2

Active, not recruiting

Prostate CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Lupron Depot

RRepros Therapeutics Inc.

Phase 3

2 2

Novantrone

Pfizer

Preclinical

5 3

Mekinist

Novartis

Preclinical

3 4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Viagra

VViatris Specialty LLC

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Osmitrol

BB. Braun Medical Inc.

Statin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Prostate Cancer

NCT05169112

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Effect of GTx-758 on Total and Free Testosterone Levels in Men With Prostate Cancer

Terminated·GGTx·Phase 2·NCT01326312·159 enrolled

Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Recruiting·OOttawa Hospital Research Institute·Phase 3·NCT05169112·72 enrolled

Uterine Fibroid1 trial

Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids

Terminated·RRepros Therapeutics Inc.·Phase 2·NCT00683917·10 enrolled

Metastatic Prostate Cancer1 trial

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02059213·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Lupron Depot. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lupron Depot compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lupron Depot. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Repros Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: RRepros Therapeutics Inc.

Lupron Depot

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Prostate Cancer2 trials

Uterine Fibroid1 trial

Metastatic Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News